EuropaWire1 天
Sanofi’s Sarclisa Receives Approval in China for Newly Diagnosed Multiple Myeloma Treatment
Sarclisa (isatuximab) has been approved in China for use in combination with the VRd regimen to treat newly diagnosed multiple myeloma patients w ...
PharmiWeb2 天
Sarclisa is the first anti-CD38 treatment approved…
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...
PharmiWeb2 天
Sarclisa is the first anti-CD38 treatment approved in China for patients with newly ...
The National Medical Products Administration (NMPA) in China has approved Sarclisa, in combination with a standard-of-care regimen, bortezomib, lenalidomide, and dexamethasone (VRd), for the treatment ...